Alamgeer M, et al. - In view of the findings from preclinical studies in small cell lung cancer (SCLC) that hyaluronic acid (HA) can be effectively used to deliver chemotherapy and selectively decrease CD44 expressing (stem cell-like) tumour cells, researchers plan to confirm the findings and obtain data on safety and activity of HA-irinotecan (HA-IR). As per findings, HA-IR can be effective in providing a survival benefit to the patients with CD44s positive tumours. In ES-SCLC, HA-IR is well tolerated and active. HA-IR had an effect on CD44s + cancer stem-like cells providing an early hint towards a potential novel target.